Guillain-Barre Syndrome Clinical Trial
Official title:
Efficacy of Mini-pool Intravenous Immunoglobulin (MP-IVIG) Prepared by Assiut University Hospital Blood Bank in Guillain-Barré Syndrome
1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG) 2. to determine the efficacy of intravenous immunoglobulin (IVIg) in hastening recovery and reducing the complications of Guillain-Barré syndrome (GBS). - The MP-IVIG was tolerated and presented no safety issues in a previous study and we will be confirmed by monitoring any adverse events (anaphylaxis and haemolysis) ( no or mild or moderate) and reporting them to ethical committee safety monitoring group. - Efficacy will be confirmed by: 1. Patient able to walk 2. Improvement of general health. 3. Integration in to social live 3. to compare the efficacy of IVIg to plasma exchange (PE) in hastening recovery and improving the condition of GBS
Guillain-Barré syndrome (GBS) is a frequent cause of neuromuscular paralysis occurring at all ages. The incidence of GBS is reported to be 1.2-2.3 per 100,000 per year . GBS is a post infectious disorder. The most frequently identified preceding infection is Campylobacter jejuni. Others are cytomegalovirus, Epstein-Barr virus, Mycoplasma pneumoniae, and Haemophilus influenzae . Many reports have documented the occurrence of GBS shortly after vaccinations, operations, or stressful events, but the causality and pathophysiology are still debated . Rapidly progressive weakness is the core clinical feature of GBS. By definition, maximal weakness is reached within 4 weeks, but most patients reach it within 2 to 3 weeks. Thereafter, patients enter a plateau phase that ranges from days to several weeks or months . This phase is followed by a usually much slower and variable recovery phase. In Europe, about one-third of GBS patients remain able to walk ("mild patients") .about 25% of the GBS patients who are unable to walk ("severe patients") need artificial ventilation. This is predominantly due to weakness of the respiratory muscles. GBS has a great impact on social life and the ability to perform activities of daily life. therefore, GBS remains a severe disease for which better treatments are required . . Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods. The preparation of the Immunoglobulin G (IgG) plasma fractionation from 20 blood donations which are tested for anti-A and anti-B titre < 32. Implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion . IVIG adverse events (AEs) are not frequent; hemolysis after IVIG is a known, rare complication. Higher doses and non-O blood group are key risk factors. The incidence of post-IVIG hemolysis is estimated at 1 per 1000 IVIG treatment episodes, most of which occur within 2 days of exposure. Although the preparation of blood group specific IVIGs in industry is a complex issue because of the pooling of thousands of plasma donations per batch, the preparation of blood group-specific mini-pool IVIG (MP-IVIG) is possible because each pool consists of only 20 plasma donations. Blood group-matched MP-IVIG is assumed to reduce the incidence of IVIG-associated hemolysis, which is largely caused by the presence of anti-A and anti-B agglutinins reacting with non-O blood group recipients. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04053452 -
Peripheral Nerve Ultrasound for Diagnosis and Prognosis of Guillain-Barre Syndrome
|
N/A | |
Recruiting |
NCT02582853 -
sCD163 as a Potential Biomarker in Guillain- Barré Syndrome
|
N/A | |
Completed |
NCT00056810 -
Assessment of Chronic Guillain-Barre Syndrome Improvement With Use of 4-aminopyridine
|
Phase 2 | |
Completed |
NCT05104762 -
IVIG Versus Plasmapheresis in the Treatment of Guillian Barrie Syndrome Patients
|
Phase 2/Phase 3 | |
Recruiting |
NCT05630313 -
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
|
||
Recruiting |
NCT03801135 -
Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation
|
N/A | |
Active, not recruiting |
NCT01655394 -
Change of Nerve Conduction Properties in IVIg Dependent Neuropathies
|
N/A | |
Completed |
NCT04927598 -
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
|
||
Completed |
NCT06334796 -
Artificial Intelligence-powered Virtual Assistant for Emergency Triage in Neurology
|
Early Phase 1 | |
Not yet recruiting |
NCT04092140 -
Neuromuscular Ultrasound in Correlation to Neurophysiological Findings
|
||
Withdrawn |
NCT03268304 -
Feasibility of Two New Software Modules for the Rehabilitation of Patients With Neuromuscular Upper Limb Impairments
|
||
Not yet recruiting |
NCT05701189 -
Evaluating Efgartigimod in Patients With Guillain-Barré Syndrome
|
Phase 2 | |
Withdrawn |
NCT02459808 -
Gastrointestinal Transit Time in Patients With Guillain-Barré Syndrome
|
N/A | |
Completed |
NCT04752566 -
A Study to Evaluate the Efficacy and Safety of Eculizumab in Guillain-Barré Syndrome
|
Phase 3 | |
Completed |
NCT05292690 -
An Assistive Powered Wheelchair: Stage 2 Trial
|
||
Not yet recruiting |
NCT06300359 -
Prognostic Indicators of Gullian-Barre Syndrome
|
||
Completed |
NCT00575653 -
Safety Study of GBS Following Menactra Meningococcal Vaccination
|
N/A | |
Completed |
NCT05491096 -
Effects of Proprioceptive Neuromuscular Training on Sensory and Motor Function in Guillain Barre Syndrome
|
N/A | |
Not yet recruiting |
NCT05114941 -
Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome
|
N/A | |
Completed |
NCT05945784 -
Exploring Accessible Beauty for Individuals With Upper Extremity Deficits
|